Diana Brainard

Insider Reports History

Reporting-owner location: Cambridge, MA
Latest reporting-owner signature: Mark A. Wilson, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Transaction source note: Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Diana Brainard

Form 4 holding Chief Executive Officer, Director

Allovir, Inc.

Security class: Common Stock
Shares / value: 723,363
Estimated value: $396,765
Report date: 19 Nov 2024
Price: $0.5485
Ownership: Direct

Form 4 holding Director

NEKTAR THERAPEUTICS

Security class: Stock Option
Shares / value: 8,000
Estimated value
Report date: 30 Sep 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Diana Brainard

4 NKTR

NEKTAR THERAPEUTICS

Report period: 30 Sep 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Oct 2025, 19:50
Role: Director
Next action: Open filing details

5 NKTR

NEKTAR THERAPEUTICS

Report period: 31 Dec 2024
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Jan 2025, 20:32
Role: Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Nov 2024
Transactions: 1
Transaction value: -$4,775
Accepted by SEC: 20 Nov 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 05 Nov 2024
Transactions: 1
Transaction value: -$9,176
Accepted by SEC: 06 Nov 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 21 Oct 2024
Transactions: 1
Transaction value: -$7,597
Accepted by SEC: 23 Oct 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 03 Oct 2024
Transactions: 1
Transaction value: -$1,216
Accepted by SEC: 04 Oct 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 20 Aug 2024
Transactions: 1
Transaction value: -$3,996
Accepted by SEC: 22 Aug 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Aug 2024
Transactions: 1
Transaction value: -$2,348
Accepted by SEC: 20 Aug 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 05 Aug 2024
Transactions: 1
Transaction value: -$7,970
Accepted by SEC: 07 Aug 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Jul 2024
Transactions: 1
Transaction value: -$7,299
Accepted by SEC: 23 Jul 2024, 16:28
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 02 Jul 2024
Transactions: 1
Transaction value: -$1,072
Accepted by SEC: 03 Jul 2024, 16:11
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 21 May 2024
Transactions: 1
Transaction value: -$4,080
Accepted by SEC: 23 May 2024, 17:24
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 17 May 2024
Transactions: 1
Transaction value: -$2,304
Accepted by SEC: 21 May 2024, 16:35
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 03 May 2024
Transactions: 1
Transaction value: -$8,151
Accepted by SEC: 07 May 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Apr 2024
Transactions: 1
Transaction value: -$7,207
Accepted by SEC: 23 Apr 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 02 Apr 2024
Transactions: 1
Transaction value: -$1,183
Accepted by SEC: 04 Apr 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 20 Feb 2024
Transactions: 2
Transaction value: -$5,803
Accepted by SEC: 22 Feb 2024, 16:18
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 05 Feb 2024
Transactions: 1
Transaction value: -$27,752
Accepted by SEC: 06 Feb 2024, 16:38
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 23 Jan 2024
Transactions: 1
Transaction value: -$6,369
Accepted by SEC: 25 Jan 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 04 Jan 2024
Transactions: 1
Transaction value: -$1,063
Accepted by SEC: 08 Jan 2024, 16:15
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 17 Nov 2023
Transactions: 2
Transaction value: -$11,794
Accepted by SEC: 21 Nov 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Oct 2023
Transactions: 1
Transaction value: -$13,558
Accepted by SEC: 23 Oct 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 03 Oct 2023
Transactions: 1
Transaction value: -$2,619
Accepted by SEC: 05 Oct 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 NKTR

NEKTAR THERAPEUTICS

Report period: 19 Sep 2023
Transactions: 1
Transaction value: $0
Accepted by SEC: 20 Sep 2023, 20:07
Role: Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 17 Aug 2023
Transactions: 2
Transaction value: -$39,664
Accepted by SEC: 21 Aug 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Jul 2023
Transactions: 1
Transaction value: -$29,710
Accepted by SEC: 21 Jul 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 05 Jul 2023
Transactions: 1
Transaction value: -$16,063
Accepted by SEC: 06 Jul 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 18 May 2023
Transactions: 1
Transaction value: -$19,115
Accepted by SEC: 19 May 2023, 17:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Apr 2023
Transactions: 1
Transaction value: -$31,183
Accepted by SEC: 21 Apr 2023, 16:05
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 21 Feb 2023
Transactions: 1
Transaction value: -$33,935
Accepted by SEC: 23 Feb 2023, 16:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 02 Feb 2023
Transactions: 2
Transaction value: $0
Accepted by SEC: 03 Feb 2023, 16:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 19 Jan 2023
Transactions: 1
Transaction value: -$174,851
Accepted by SEC: 23 Jan 2023, 18:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 18 Nov 2022
Transactions: 1
Transaction value: -$32,810
Accepted by SEC: 21 Nov 2022, 16:47
Role: Chief Executive Officer, Director
Next action: Open filing details

4 NKTR

NEKTAR THERAPEUTICS

Report period: 16 Sep 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 20 Sep 2022, 20:43
Role: Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 18 Aug 2022
Transactions: 1
Transaction value: -$35,429
Accepted by SEC: 19 Aug 2022, 16:05
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 16 Aug 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 17 Aug 2022, 17:59
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 01 Jul 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 06 Jul 2022, 07:30
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 18 May 2022
Transactions: 1
Transaction value: -$126,257
Accepted by SEC: 23 May 2022, 16:44
Role: Chief Executive Officer, Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 18 Jan 2022
Transactions: 2
Transaction value: $0
Accepted by SEC: 04 Apr 2022, 16:23
Role: Chief Executive Officer, Director
Next action: Open filing details

4 NKTR

NEKTAR THERAPEUTICS

Report period: 11 Nov 2021
Transactions: 2
Transaction value: $0
Accepted by SEC: 15 Nov 2021, 16:08
Role: Director
Next action: Open filing details

3 NKTR

NEKTAR THERAPEUTICS

Report period: 11 Nov 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 15 Nov 2021, 16:06
Role: Director
Next action: Open filing details

4 KLRS

Allovir, Inc.

Report period: 17 May 2021
Transactions: 3
Transaction value: $0
Accepted by SEC: 18 May 2021, 17:08
Role: Chief Executive Officer, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .